 The primary objective of this study is to demonstrate the feasibility and safety of intra-operative, intra-myocardial injection of autologous CD133 positive bone marrow cells at the time of coronary artery bypass graft CABG surgery in patients with chronic ischemic cardiomyopathy. Additionally, the feasibility of producing autologous CD133 bone marrow stem cells will be assessed. 